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Major histocompatibility complex antigens are critical to an animal's immune response. In
most animals, the extreme polymorphism of MHC molecules complicates studies of the role of
this complex in the immune response. In mice, however, MHC haplotype-homozygous inbred
strains have been developed which are invaluable in the study of the immune system and the
search for immune response genes. The human MHC bears many similarities to its murine
equivalent with regard to antigen structure and polymorphism; furthermore, a number of
combinations ofspecific MHCallelesbetween HLA-B and HLA-DR/DQ (extended haplotypes)
are found in people more commonly than predicted by individual allele frequencies. Over 30
percentofCaucasian haplotypes areextended haplotypes, and over 55 percentofindividuals have
at least one extended haplotype. Examples of the same extended haplotype, even in unrelated
individuals, should either all have or lack any gene within the MHC region. The value of
considering extended haplotypes in searching for associations between the MHC and diseases, or
immune response, is shown in three examples: congenital adrenal hyperplasia, hepatitis B
immunization, andtransfusion-associated graft-versus-host disease.
INTRODUCTION
An elaborate system ofhost defense has evolved in animals to allow an organism to
defend itself from invasion by other species. Graft rejection has proven to be an
excellent test for the presence of a functional immune system. Although the recogni-
tion and rejection offoreign grafted tissues may not be a normal physiologic function,
graft rejection involves processes very similar to those used in identifying viral and
other foreign organisms and antigens. Studies have shown that all vertebrate animals
arecapableofgraftrejection, and thatthis phenomenon correlates with the presenceof
major histocompatibility complex (MHC) antigens. The MHC is a critical factor in
this self:non-self immune recognition system: MHC cell-surface proteins, antigenic
determihants, and the T-cell receptor must interact in order to initiate humoral and
cellular immune responses. MHC proteins are highly polymorphic, and, in recent
years, additional complexities have been uncovered with the use oftechniques such as
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isoelectric focusing and restriction fragment length polymorphisms [1-4]. Such intri-
cacies have complicated study of the role of the MHC in antibody formation in
response to specific antigens, susceptibility to disease, and transplantation problems,
particularly in humans.
The mouse, on the other hand, has probably the most intensively studied and best
understood MHC complex. Immunogenetic studies in this animal have been facilitated
by the identification in thewild, and further development in thelaboratory, ofstrainsof
animals which are homozygous for particular H-2 haplotypes (inbred mice). Theuseof
these haplotype-homozygous animals, and their related variants, both congenic (one
strain's H-2 haplotype inserted into a different inbred strain) and recombinant (parts
of two different H-2 haplotypes inserted into an inbred strain), has been particularly
valuable in the identification ofimmune response genes [5]. In the process ofanalyzing
human MHC haplotypes for variations in complement alleles, Dr. Chester Alper and
his research group at the Center for Blood Research (which includes Drs. Edmond
Yunis, Zuheir Awdeh, and the author) have demonstrated that a relatively small
number ofgene combinations are surprisingly common in many unrelated individuals.
Furthermore, approximately 1 percent ofthe human population is homozygous for one
of these MHC gene combinations. Thus, as in mice, the human MHC might also
profitably be considered from the standpoint of common haplotypes ("extended
haplotypes"). In this review, I will compare the murine and human MHC, explain the
concept of extended haplotypes, and demonstrate the value of this approach in
understanding genetic linkage and aspects of the immune response important to
transfusion medicine.
THE MHC IN MICE
The murine MHC is found on chromosome 17, and the complex of these genes is
designated H-2. Haplotypes composed of specific antigen combinations are described
bylowercase letters (for example, k, d, b, f). Inbred strains ofmice arehomozygous for
one ofthese haplotypes. Three classes ofantigen comprise the MHC complex. Class I
antigens (K, D, and L) are heterodimers composed of a 45 kilodalton polypeptide
(heavy chain) coupled with beta-2-microglobulin. Antigens ofthis class are present on
the surface of nearly all cells in the mouse [6]. Extreme polymorphism exists among
class I antigens; for example, over 100 variants have been identified at each oftwo loci
(H-2K and H-2D) [6]. Class II antigens are heterodimers, consisting of an alpha
(heavy) chain of 34,000 daltons and a beta (light) chain of 29,000 daltons. These I-A
and I-E antigens, also highly polymorphic, are found on B lymphocytes, antigen-
presenting cells, and activated T lymphocytes. The position of the antigen in the cell
membraneresults ineach moleculehavingextracellular, transmembrane, andcytoplas-
mic regions. The polymorphism of these antigens is, however, found largely in the
extracellular portion, supporting the critical role ofthis region in the specificity ofthe
immune response in an animal of given haplotype [7]. The complement proteins Bf,
C2, and two forms ofC4 are encoded by genes located between class II and class I D
regions. Because of this location, complement gene products have come to be called
class III antigens, even though they are structurally distinct from the other MHC
proteins, and are not cell-surface markers.
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THE IMMUNE RESPONSE OF THE MOUSE IS DICTATED
BY H-2 HAPLOTYPE
Class I and II proteins are critical ingredients in the process of foreign antigen
recognition. Their primary role may be the binding and presentation of peptide
antigens to T cells. T cells expressing the protein CD4 (helper T cells) recognize
antigen only in the presence ofclass II gene products, leading to B-cell activation and
antibody production. T cells which express CD8, on the other hand, recognize antigen
in the presence of class I proteins as a prerequisite for cytotoxicity. Although class I
and class II MHC proteins have the capacity to bind many different types ofpeptides,
individual MHC proteins have binding preferences such that not all peptide antigens
are bound equally well, and some are not bound at all (peptide specificity). This
selectivity probably also affects the ability ofthe MHC-antigen combination to trigger
T-cell recognition [8]. Thedevelopment ofMHCdiversity is believed by manyworkers
to be advantageous to an organism and species. Without such genetic variability,
vulnerability to certain pathogens may emerge, with devastating consequences. For
example, the cheetah is currently considered an endangered species. All cheetahs
which have been studied have identical MHC markers. The species' lack of MHC
polymorphism appears to have rendered cheetahs nearly uniformly susceptible to a
fatal feline infectious peritonitis caused by a coronavirus [9].
In mice, antibody responses to a variety of different synthetic peptides have been
shown to be determined by genes mapping to the region ofthe MHC. Thus, strains of
mice bearing the haplotype H-2k (for example, CBA and C58/J strains) are poor
responders to the synthetic antigen (T,G)-A-L, while animals with the haplotype H-2d
(BALB/c and NZB strains) are intermediate, and those with the haplotype H-2b
(C57) are high responders [10]. Subsequent experiments have suggested that numer-
ous immune response genes exist, because the level of antibody response in a given
inbred strain varies with the antigen used, and good response to one antigen does not
guarantee good response with others. Current thinking suggests that the poor respon-
siveness occurs because an abnormal or absent immune response gene results in T cells
from such animals being unable to recognize a particular antigen-plus-MHC-protein
complex. This lack ofrecognition could be due to one ofseveral reasons: the appropri-
ate T-cell clone is not produced (a "hole" in the T-cell repertoire); such cells are
produced but eliminated early in development ("negative selection"); the foreign
antigen and MHC proteins are unable to bind in a manner sufficient for T-cell
recognition; or the MHC-antigen pair leads to preferential stimulation ofT suppressor
rather than T helper cells.
THE MAJOR HISTOCOMPATIBILITY COMPLEX IN HUMANS
The human MHC is found on the short arm of the sixth chromosome and encom-
passes more than 3.5 million base pairs ofDNA, or 2 percent ofthe total chromosome
[11,12]. Similar to the MHC in mice, three classes ofantigen are produced by human
MHC genes. Class I antigens are heterodimers composed of a 45 kilodalton MHC-
encoded heavy chain coupled with beta-2-microglobulin, a 12 kilodalton product of a
gene on chromosome 15. Theseantigens (HLA-A, -B, and -C) arefound on thesurface
of all nucleated cells and are critical to antigen recognition by cytotoxic T cells. The
structure ofthe HLA-A2 molecule has recently been determined throughcrystallogra-
phy; the alpha 1 and alpha 2 domains oftheheavy chain form the sides ofa cleft, which
appears to bind antigenic peptides for recognition by T cells [13]. Class II antigens are
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also very similar to their murine equivalents in size, structure, and location on B
lymphocytes, macrophages and other antigen-presenting cells, and activated T lympho-
cytes. The antigens, including HLA-DR, -DQ, and -DP, are critical to soluble antigen
recognition by helper T cells. There is much structural similarity between human and
murine antigens-for example, some regions of hypervariability in the extracellular
portion of class II antigens occur at the same residues [7]. Such conservation over
evolution between species presumably occurred because the proteins served valuable,
and similar, immunologic functions; such similarities strengthen the value ofthe mouse
as an immunologic model. There are also differences-for example, the mouse does not
appear to have the DP region, and man has more genes for the alpha chain of class II
proteins (six) than the mouse (two) [7]. As in mice, genes for three complement
proteins (Factor B, C2, and the two variants of C4) are found nestled between class I
and class II genes. In addition to these genes, there are many others in the MHC
region, including genes for the adrenal steroid 21-hydroxylase, tumor necrosis factor, a
heat shock protein, proteins of unknown function, such as the so-called HLA-B-
associated transcripts, and large stretches of genomic DNA without identified func-
tional gene products.
As they are in mice, the genes ofthe human MHC are highly polymorphic, including
at least 24 variants of HLA-A, 52 variants of HLA-B, 11 of HLA-C, 20 of HLA-DR,
nine of HLA-DQ, and six of HLA-DP [14]. Such polymorphisms may have been
important in an evolutionary sense in the development of immunity, although, ironi-
cally, at the expense of a greater likelihood ofgraft rejection [12].
THE SEARCH FOR IMMUNE RESPONSE GENES IN MAN.
While it is extremely likely that the human MHC is critical to immune response,
both against foreign and self antigens, few experiments have yielded results as clear as
those in mice. Formost immunologic disorders where an association with the MHC has
been sought, analysis of observations in populations have been hampered by MHC
polymorphism, as well as by many confounding clinical factors such as ethnic variation
in the distribution of MHC alleles, environmental factors, and the additive effects of
non-MHC genes.
Our group and others have noted, however, that combinations of specific alleles are
found together in some people much more commonly than individual allele frequencies
would have predicted. For example, the frequency of HLA-B8-positive Caucasians in
Boston is approximately 26 percent, and the frequency of HLA-DR3-positive individu-
als in the same population is 28 percent. Nearly all antigen-positive individuals are
heterozygous, rather than homozygous, for these antigens; therefore the allele fre-
quency of HLA-B8 can be estimated from the Hardy-Weinberg equation as being
roughly half, or 13 percent, and the frequency of HLA-DR3 as 14 percent. If HLA-B8
and -DR3 were inherited independently, the combination of HLA-B8 and -DR3 should
have a frequency of less than 2 percent(0.14 x 0.13), and in the Boston population
fewer than 4 percent ofindividuals would have this allele combination. Instead, over 10
percent of individuals are B8,DR3-positive [14]. Furthermore, nearly all haplotypes
also carry a specific combination of class III complement genes: BF*S, C2*C,
C4A*QO, and C4B*J (encoding for the BF protein S, the C2 protein C, an absence of
C4A, and the C4B variant 1; for convenience, this combination is abbreviated as
"SCO
1" in describing its presence in haplotypes). Population studies in our laboratory
have revealed at least 12 such sets of alleles encompassing the region between HLA-B
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TABLE 1
Common Extended MHC Haplotypes in Whites
Frequency of Frequencyof Chance of
Haplotype Heterozygous Homozygous Transfusion
Frequency in Individuals Individuals Random Donor B to
Extended Haplotype Whites (%) (A) (%) (B) (%) Recipient A (%)
[HLA-(Al),B8,SCOI,DR3] 9.2 16.7 0.8 0.1
[HLA-(A3),B7,SC31,DR2] 6.8 12.7 0.5 0.1
[HLA-(A29),B44,FC31,DR7] 3.0 5.8 0.1 <0.1
[HLA-(A2),B44,SC30,DR4] 2.9 5.7 0.1 <0.1
[HLA-(Al),Bw57,SC61,DR7] 2.0 3.9 <0.1 <0.1
[HLA-(A33),B14,SC21,DRl] 1.4 2.7 <0.1 <0.1
[HLA-(A26),B38,SC21,DR4] 0.9 1.8 <0.1 <0.1
[HLA-(A2),B15,SC33,DR4] 0.9 1.8 <0.1 <0.1
[HLA-(A3),B35,FC3.20,DR1] 0.9 1.8 <0.1 <0.1
Total 28.1 53.0 1.6 0.2
In addition to HLA-B and -DR results, the haplotypes include the complement alleles BF, C2, C4A, and
C4B, in that arbitrary order. Thus, theabbreviation SCOI stands fortheS alleleofBF, the C alleleofC2,
absence ofC4A, and theC4Ballele 1. The most frequently associated HLA-A allele for each haplotype is
shown in parentheses (from [32]).
and HLA-DR,DQ (in most of these haplotypes, one HLA-A allele predominates,
although there is some variability at this locus). We have called these combinations
fixed or "extended" haplotypes; other groups have appellations such as "preferred
allelic associations" or "ancestral haplotypes" [14]. Whether, and if so why, such
combinations have been preferentially preserved over time is not clear, but some
authors have hypothesized either crossover suppression, or restricted crossover capac-
ity of extended haplotypes [15]. In total, these combinations are found in over 30
percent of Caucasian chromosomes; over 55 percent of individuals have one extended
haplotype, and 1.6 percent of individuals are homozygous for such a haplotype [15].
Nine ofthe most common haplotypes are shown in Table 1.
Because the DNA appears fixed for each haplotype over at least the HLA-B through
HLA-DR/DQ interval, we believe that these gene combinations are of great value in
understanding the human immune response. For example, an individual MHC allele
which appears to bea marker for a disease may be so not becausethe antigen is directly
responsible, butonlybecauseit marks anextended haplotype, all ornearlyall examples
of which also bear another etiologic gene. In looking for the presence of an immune
responseor immune suppression genein man, a search forcorrelation with thepresence
(or absence) of extended haplotypes can be a much more potent analysis than a
relationship to an individual allele, since examples of the same fixed allelic combina-
tions should all either contain or lack the putative gene. The three examples listed
below offer testimony to thevalue ofthis concept.
Example 1: Congenital Adrenal Hyperplasia Is Associated with Two Extended
Haplotypes
An illustrative example of the value of analyses which take into account extended
haplotypes involves the syndrome of congenital adrenal hyperplasia (CAH). Even
though not an immunologic disease, this rare, recessively inherited endocrine disorder
was originally found to belinked to the MHC, and later to show linkagedisequilibrium
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FIG. 1. A map of the human MHC on the short arm of chromosome 6, with the
centromere to the left (from [11]).
with Bw47 [16], B14 (now Bw65), and DRI [17-19]. Subsequently it was shown that
the gene for 21-hydroxylase, whose deficiency was responsible for thevarious manifes-
tationsofthedisease (salt- wasting versussimplevirilization, forexample), waslocated
in the MHC complex adjacent to the C4B gene. The Center for Blood Researcc
laboratory data on extended haplotypes then provided the solution for the MHC
linkage. HLA-Bw47 was part ofthe extended haplotype [HLA-Bw47,FC91,0,DR7];
this rare haplotype, present in only 0.3 percent of control subjects, was present in 40
percent ofpatients with thesalt-wasting form ofCAH. Thehaplotype has a deletion of
both C4B and 21-hydroxylase B (the active gene for the enzyme). Furthermore, Bw65
andDRI werepartofamorecommonextendedhaplotype [HLA-Bw65,SC2(1,2),DR1]
with a duplicated 21-hydroxylase B gene, which produces a defective product, and the
milder formofCAH [20,21]. Thus, in this case, MHC markers have no role in causing
disease; the association simply reflects the presence ofabnormal 21-hydroxylase genes
in certain extended haplotypes (Fig. 1).
Example 2: At Least One ExtendedHaplotype IsAssociated with Non-Response to
the Hepatitis B Vaccine
As with other peptide antigens, different inbred strains of mice have variable
responses to the hepatitis B surface antigen, depending on the H-2 haplotype. For
example, strains with the haplotypes H-2f and H-2' respond poorly, whereas other
strains develop normal oreven elevated levels ofantibody [22]. Fl heterozygotes oftwo
different inbred mouse strains will respond to HBsAg provided that one parent is a
responder. This effect suggests that responder haplotypes bear an immune response
gene which is expressed dominantly.
In early studies of the efficacy of the hepatitis B vaccine in healthy human
volunteers, the Center for Blood Research and collaborators found that approximately
4 percent of recipients made little or no antibody (<36 RIA units) following a
three-injection course [23]. Similar proportions of non-responders have consistently
been found by other groups [24,25]. To explore a possible relationship between poor
response to the vaccine and the MHC, 20 non-responders were typed for HLA
markers. Three of these individuals typed as apparent homozygotes for extended









FIG. 2. Serum antibody to hep-
10,000 atitis B surface antigen measured
two months after completion of a
* standard course of immunization
5,000 with hepatitis B vaccine. Results
in individuals homozygous for the
extended haplotype [HLA- O ~~~~~~~~~~~~~~B8,SCOI,DR3] on the left, and
HLA-B8,SCO1,DR3 HLA-B8,SCO1,DR3 heterozygous for this haplotype,
homozygous heterozygous on theright [23].
haplotypes (15 percent), a tenfold excess over the expected incidence of individuals
with homozygous haplotypes in the general population (1.6 percent, Table 1).
Two non-responders were apparent homozygotes for the extended haplotype
[HLA-B8,SC01,DR3], and one for [HLA-B44,FC31,DR7] [23]. Furthermore, when
we prospectively vaccinated 14 individuals bearing either one or two [HLA-
B8,SCO1,DR3] chromosomes, the five homozygous individuals all had poor or absent
antibody responses (mean, 467 RIA units; range, <8-1,266) two months following the
third injection (Fig. 2). The heterozygous individuals had substantially different levels
(mean, 15,608; range, 2,655-28,900) [26].
These results in humans suggest that the production ofantibody to HBsAg is, as in
mice, a dominant trait. Individuals homozygous for the extended haplotype [HLA-
B8,SCO1,DR3] appeartolackanimmuneresponsegenewhichrecognizes thehepatitis
B surfaceantigen. Further studies are in progress todocument the mode ofinheritance
in families where at least one individual is a homozygote. This relationship between
lack of response to a protein antigen and MHC homozygosity may be the first clear
demonstration in man of an immune response gene. Cells and DNA from these
haplotype-homozygous individuals offer a valuable tool for dissecting the location of
this and other genes and their functions.
Example 3. Graft-Versus-Host DiseaseFollowing Transfusion Can Occur When the
BloodDonor IsHomozygousfor an ExtendedHaplotype, and the Recipient Is
Heterozygousfor It
In the mouse and other animal species, transfusion of immunocompetent T cells
from a homozygous (inbred) parent to an offspring heterozygous for the parent's
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haplotype regularly produces graft-versus-host (GVH) disease. This process occurs
because the donor lymphocytes, being fully HLA-identical with markers encoded by
one of the recipient's chromosomes, can escape detection and react against MHC
markers encoded by the recipient's other chromosomes [27,28]. In humans, reactivity
in mixed lymphocyte culture between unrelated individuals matched for common
extended haplotypes has been shown to be as low as that between MHC-identical
siblings [29]. Because any two examples of the same extended haplotype in unrelated
individuals are immunologically similar, an individual homozygous for an extended
haplotype can be considered analogous to inbred, MHC-homozygous (haplotype-
identical) animals in terms ofimmunologic recognition.
HLA typing has only rarely been successful in transfusion-associated GVH in
humans; samples are often unobtainable because the patient rapidly develops extreme
lymphopenia or dies before the diagnosis is considered. In some of the cases where at
least partial typing has been done, however, extended-haplotype-homozygous donors
have been implicated. For example, a donor apparently homozygous for antigens
contained in the haplotype [HLA-B8,SC0l,DR3] caused fatal GVH in an unrelated
recipient with Hodgkin's disease [30]. Another donor, apparently homozygous for
HLA-B12 (parent group of B44, found in two common extended haplotypes), caused
fatal GVH in a newborn [31]. Furthermore, in a recent report from Israel, a fresh
red cell component from a donor homozygous for the antigens HLA-A26,B38,DR4
(and therefore very likely for the Caucasian extended haplotype [HLA-
A26,B38,SC21,DR4]) caused fatal GVH in his haplotype-heterozygous, seemingly
immunocompetent, father [32]. Blood from an unrelated haplotype-homozygous donor
(the common Japanese haplotype [HLA-A24,CBL,Bw52,DR2,DRw52,DQwl] has
been implicated in two cases ofGVH in normal Japanese recipients [33,34].
The probability that blood from a donor homozygous for any extended haplotype
might be transfused to a recipient heterozygous for the same haplotype can be
calculated, and proves to bequite high in Caucasians (approximately 1 in 500;Table 1)
[35]. The odds ofsuch a donor:recipient combinationoccurring are increased when the
donor is a first-degree relative of the recipient, explaining the recent rash of reports
involving so-called directed donations [32,36]. Reports oftransfusion-associated GVH
are far less common than the calculations predict, however, and in fact still quite rare
in immunocompetent individuals. Mitigating factors, such as the number and viability
of transfused lymphocytes, may be important; alternatively, GVH may be underdiag-
nosed. Retrospective analyses ofthe incidence and recipient population characteristics
oftransfusion-associated graft-versus-host disease would help to answer this question.
Prospective studies ofthe fate oftransfused lymphocytes from haplotype-homozygous
donors would beextremelyvaluable but may not beadvisable,given the theoretical risk
ofGVH; other in vitrostudies may need to besubstituted to understand this syndrome.
CONCLUSION
Although the MHC is a complex system, the recognition ofcommon gene combina-
tions in humans, or extended haplotypes, hasclarified, and sometimes identified for the
first time, relationships between MHC genes and immunologic function and dysfunc-
tion. Many questions can be explored using this approach-the relationship between
specific haplotypes and gluten-sensitive enteropathy [37], pemphigus vulgaris [38],
and diabetes [39], for example. Others merit possible consideration-for example,
could unrelated bone marrow donors be chosen based on extended haplotype matching
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(which we would predict could be successful despite selective HLA-A allele mismatch-
ing)? The concept of extended haplotypes should provide a useful framework for
interpreting data from avarietyofstudies ofthe immunesystem overthecoming years.
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